Drug
Rilpivirine clinical trials
Also written TMC278 and Edurant.
- studies test it
- 60
- open now
- 1
- in phase 3
- 16
- first study started
- 2005
Keep track of what changes. Save the Rilpivirine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Studies by the year they started
60 studies that test it; most in 2012 (10)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2008 | 7 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 10 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 25
- Phase 2
- 14
- Phase 3
- 16
- Phase 4
- 9
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 40 · Other 20
Tibotec Pharmaceuticals, Ireland (13) · ViiV Healthcare (10) · Janssen Research & Development, LLC (4) · Janssen R&D Ireland (4) · Janssen Sciences Ireland UC (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Mahidol University (3) · St Stephens Aids Trust (3)
Often tested with
Tested in the same studies.
Cabotegravir (11) · Tenofovir (7) · Emtricitabine (6) · Darunavir (5) · Ritonavir (3) · Efavirenz (3) · Cobicistat mixture with darunavir (2) · Azvudine (1)
Studies
Open first, then newest update. How each study uses Rilpivirine is read from its arms, and is right about nine times in ten.
Testing it · 60
- Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in PediatricsRecruitingPhase 1/2ViiV HealthcareNCT05674656Written as Dolutegravir/Rilpivirine FDC
- Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected AdultsActive, not recruitingPhase 3ViiV HealthcareNCT03299049Written as Rilpivirine Tablets
- The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifECompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT03635788Written as Oral RPV
- A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric StudiesActive, not recruitingPhase 2Janssen Sciences Ireland UCNCT02494986Written as Rilpivirine
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsActive, not recruitingPhase 3ViiV HealthcareNCT02938520Written as Rilpivirine (RPV) tablet
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsActive, not recruitingPhase 3ViiV HealthcareNCT02951052Written as Rilpivirine (RPV) tablet
- More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and AdolescentsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT03497676Written as Oral Rilpivirine (RPV)
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rilpivirine Tablets (RPV)CompletedPhase 1Henan Genuine Biotech Co., Ltd.NCT07001488Written as Azvudine tablets(FNC) and Rilpivirine Tablets (RPV)
- A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically SuppressedCompletedPhase 2Janssen Research & Development, LLCNCT04012931Written as Rilpivirine
- A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT03127189Written as Rilpivirine
- Relative Bioavailability of Three Oral Formulations Candidates of Rilpivirine for Potential Pediatric Use Compared to Oral TabletCompletedPhase 1Janssen Sciences Ireland UCNCT02561936Written as Rilpivirine Oral Tablet
- Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR StudyCompletedPhase 3ViiV HealthcareNCT05896748Written as Rilpivirine - Injectable Suspension (RPV LA)
- A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) InfectionTerminatedPhase 3Janssen Research & Development, LLCNCT03563742Written as Rilpivirine 25 mg
- A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 YearsCompletedPhase 2Janssen Sciences Ireland UCNCT00799864Written as Rilpivirine
- A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically SuppressedCompletedPhase 3ViiV HealthcareNCT04542070Written as Rilpivirine Tablets
- Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult ParticipantsCompletedPhase 1ViiV HealthcareNCT04371380Written as Rilpivirine Tablets
- A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected ParticipantsCompletedPhase 3ViiV HealthcareNCT05896761Written as Rilpivirine Injectable Suspension
- Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of AgeWithdrawnPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT01975012Written as Rilpivirine
- FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral ReservoirCompletedPhase 4Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT01777997Written as Emtricitabine/rilpivirine/tenofovir disoproxil fumarate
- Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/TenofovirCompletedPhase 2/3Philip GrantNCT02104700Written as Rilpivirine/Emtricitabine/Tenofovir
See all 60 studies that test Rilpivirine →
Given in every arm · 3 — Rilpivirine is usual care beside what is tested
- A Study of a Rilpivirine Extended-Release Suspension in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT05112939Written as RPV LA
- A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on PharmacokineticsCompletedPhase 1Janssen Infectious Diseases BVBANCT02547870Written as Rilpivirine (RPV)
- A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult SubjectsCompletedPhase 1ViiV HealthcareNCT01467531Written as Rlipivirine
As the comparator · 3 — what is tested is compared with Rilpivirine
- Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyRecruitingPhase 3Gilead SciencesNCT07682961Written as Rilpivirine
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV NaiveWithdrawnPhase 4Juan A. ArnaizNCT02470650Written as rilpivirine
- A Study of Bioavailability and Food Effect of SACT-1 and Edurant® Tablets in Healthy Adult VolunteersCompletedPhase 1Aptorum International LimitedNCT05358756Written as EDURANT 25Mg Tablet
Codes
What other systems call Rilpivirine · ClinicalTrials.gg INT006530
- MeSH (NLM) D000068696RilpivirineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) FI96A8X663RILPIVIRINEConfirmed FDA, NLM, Wikidata
- RxNorm 1102270Confirmed FDA, Wikidata
- Wikidata Q421547rilpivirineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76929RilpivirineOne source FDA
- DrugBank DB08864One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068696 | Rilpivirine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | FI96A8X663 | RILPIVIRINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1102270 | — | Confirmed FDA, Wikidata |
| Wikidata | Q421547 | rilpivirine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76929 | Rilpivirine | One source FDA |
| DrugBank | DB08864 | — | One source Wikidata |
Also registered as rilpivirine hydrochloride (UNII 212WAX8KDD · RxNorm 1102287).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.